Summary Box: Amgen CEO Sees Higher Sales In 2012

Published January 9, 2012 9:45PM (EST)

RISING TIDE: Robert Bradway, on deck as Amgen's next CEO, predicts newer products and expanding operations into more countries to bring higher revenue down the road.

MOMENTUM: Positive developments include last year's purchase of a cancer vaccine developer and moves to protect long-term sales of top seller Enbrel, for psoriasis and rheumatoid arthritis, and anemia treatment Epogen.

MANAGEMENT MOVES: Along with Bradway, Amgen has appointed new heads of commercial operations and research and development. It also plans more share buybacks.

By Salon Staff

MORE FROM Salon Staff

Related Topics ------------------------------------------